Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients
Public ClinicalTrials.gov record NCT01399957. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Responsiveness to Dalfampridine Treatment Among Multiple Sclerosis Patients Followed at the Mandell MS Center: Characterizing Clinical Predictors of Response and Identifying Additional Outcomes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Ampyra (dalfampridine-ER) was approved by the FDA (2010) for improving walking speed in persons with multiple sclerosis. This project seeks to determine if there are other benefits to taking dalfampridine besides an increase in walking speed. This is strictly an observational study and research staff will not be involved in any decisions to stop or start taking the medication.
Study identification
- NCT ID
- NCT01399957
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 52 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2010
- Primary completion
- Aug 31, 2014
- Completion
- Aug 31, 2015
- Last update posted
- Nov 9, 2015
2010 – 2015
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mandell Center for Multiple Sclerosis at the Mount Sinai Rehabilitation Hospital | Hartford | Connecticut | 06112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Multiple Sclerosis trials
Other public records listing Multiple Sclerosis. Sorted by last update posted; newest first. Not a recommendation.
- NCT07779460: A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice Recruiting
- NCT07768761: Electrical Stimulation Exercise for Individuals With Lower Limb Paralysis Recruiting
- NCT07759115: Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study Not yet recruiting
- NCT05057676: Autoimmune Intervention Mastery Course Study Active, not recruiting
- NCT06233370: Acute Effects of Walking Exercise on Brain Functioning in Multiple Sclerosis Active, not recruiting
- NCT07115017: This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis. Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01399957, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2015 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01399957 live on ClinicalTrials.gov.